Long-term efficacy and safety of deferasirox

Blood Reviews

Volumn 22, Issue SUPPL. 2, 2008, Pages

  Cappellini, Maria Domenica ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Deferasirox; Iron chelation therapy; Iron overload; Long term efficacy; Safety

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ARTHRALGIA; BETA THALASSEMIA; BLOOD TRANSFUSION; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISEASE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HUMAN; HYPOACUSIS; IRON BALANCE; IRON CHELATION; IRON OVERLOAD; LIVER FUNCTION TEST; LIVER TOXICITY; LONG TERM CARE; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; SICKLE CELL ANEMIA; SIDE EFFECT; SKIN MANIFESTATION;

ADOLESCENT; BENZOIC ACIDS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; TRIAZOLES;

EID: 57049084100     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(08)70007-9     Document Type: Review

References (36)

1. Hider R.C., and Zhou T. The design of orally active iron chelators. Ann NY Acad Sci 1054 (2005) 141-154
2. Olivieri N.F., and Brittenham G.M. Iron-chelating therapy and the treatment of thalassaemia. Blood 89 (1997) 736-761
3. Deferoxamine (Desferal®) package insert. Novartis 2002.
4. Kushner J.P., Porter J.P., and Olivieri N.F. Secondary iron overload. Hematology Am Soc Hematol Educ Program (2001) 47-61
5. Deferiprone (Ferriprox®) package insert. Apotex Europe Ltd. 1999.
6. Cappellini M.D., Cohen A., Piga A., et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassaemia. Blood 107 (2006) 3455-3462
7. Deferasirox (Exjade®) package insert. Novartis 2005.
8. Thalassaemia International Federation. Iron overload. Guidelines for the Clinical Management of Thalassaemia. 2nd Ed. (2007), Nicosia, Cyprus 31-63
9. Wonke B., Wright C., and Hoffbrand A.V. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 106 (1998) 252-253
10. Piga A., Roggero S., Vincinguerra T., et al. Deferiprone: new insight. Ann NY Acad Sci 1054 (2005) 169-174
11. Peng C.T., Wu K.H., Wu S.F., et al. Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan. Hemoglobin 30 1 (2006) 125-130
12. Kolnagou A., and Kontoghiorghes G.J. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassaemia. The Protocol of the International Committee on Oral Chelators. Hemoglobin 30 (2006) 239-249
13. Daar S., and Pathare A.V. Combined therapy with desferrioxamine and deferiprone in beta thalassaemia major patients with transfusional iron overload. Ann Hematol 85 (2006) 315-319
14. Mourad F.H., Hoffbrand A.V., Sheikh-Taha M., et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 121 (2003) 187-189
15. Gomber S., Saxena R., and Madan N. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. Indian J Pediatr 41 (2004) 21-27
16. Galanello R., Kattamis A., Piga A., et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassaemia. Haematologica 91 (2006) 1241-1243
17. Aydinok Y., Ulger Z., Nart D., et al. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassaemia major. Haematologica 92 (2007) 1599-1606
18. Tanner M.A., Galanello R., Dessi C., et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance. Circulation 115 (2007) 1876-1884
19. Tanner M.A., Galanello R., Dessi C., et al. Combined chelation therapy in thalassaemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 25 (2008) 12
20. Piga A., Galanello R., Forni G.L., et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassaemia patients with transfusional iron overload. Haematologica 91 (2006) 873-880
21. Galanello R., Piga A., Forni G.L., et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in paediatric patients with beta-thalassaemia major. Haematologica 91 (2006) 1343-1351
22. Cohen A.R., Glimm E., and Porter J.B. Effect of transfusional iron intake on response to chelation therapy in beta-thalassaemia major. Blood 111 (2008) 583-587
23. Cappellini M.D., Bejaoui M., Agaoglu L., et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassaemia. Clin Ther 29 (2007) 909-917
24. Vichinsky E., Onyekwere O., Porter J., et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 136 (2007) 501-508
25. Vichinsky E., Pakbaz Z., Onyekwere O., et al. Patient-reported outcomes of deferasirox (Exjade(R), ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial. Acta Haematol 119 (2008) 133-141
26. Porter J., Galanello R., Saglio G., et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 80 (2008) 168-176
27. List A.F., Baer M.R., Steensma D., et al. Deferasirox (ICL670; Exjade®) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS). Blood 110 (2007) abstract 1470.
28. Cappellini M.D., Vichinsky E., Ford J.M., et al. Evaluation of deferasirox (Exjade®, ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) (less than or equal to) 1000 ng/mL in long-term studies. Blood 110 (2007) abstract 3795.
29. Cappellini M.D., Vichinsky E., Galanello R., et al. Long-term treatment with deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, is effective in patients with transfusion-dependent anaemias. Blood 110 (2007) abstract 2777.
30. Porter J.B., Cohen A.R., Ford J.M., et al. Impact of dose adjustments on serum ferritin (SF) levels during long-term treatment with once-daily, oral deferasirox (Exjade®, ICL670). Blood 110 (2007) abstract 2778.
31. Piga A., Vichinsky E., Forni G.L., et al. Long-term efficacy and safety with deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, in paediatric patients. Blood 110 (2007) abstract 2774.
32. Vichinsky E., Coates T.D., Thompson A.A., et al. Long-term efficacy and safety of deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, in patients with sickle cell disease (SCD). Blood 110 (2007) abstract 3395.
33. Gabutti V., and Piga A. Results of long-term iron-chelating therapy. Acta Haematol 95 (1996) 26-36
34. Olivieri N.F., Nathan D.G., MacMillan J.H., et al. Survival in medically treated patients with homozygous beta-thalassaemia. N Engl J Med 331 (1994) 574-578
35. Telfer P.T., Prestcott E., Holden S., et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 110 (2000) 971-977
36. Borgna-Pignatti C., Rugolotto S., De Stefano P., et al. Survival and complications in patients with thalassaemia major treated with transfusion and deferoxamine. Haematologica 89 (2004) 1187-1193